

AMENDMENTS TO THE SPECIFICATION

Please amend the specification and replace paragraphs 1 and 35 with the amended paragraphs shown below.

5

(0001) This application is a divisional application under 37 C.F.R. 1.53(b) and claims priority from U.S. application Serial No. 09/535,675, filed March 23, 2000, now patent No. 6,667,299 B1, which claims priority from abandoned U.S. provisional application which is a continuation in part of Ser. No. 60/190,140,

10 filed March 16, 2000, abandoned U.S. provisional application Ser. No. 60/164,048, filed November 8, 1999, abandoned U.S. application Ser. No. 09/414,905, filed October 8, 1999, abandoned U.S. provisional application Ser. No. 60/140,028, filed June 16, 1999, and abandoned U.S. provisional application Ser. No. 60/126,056, filed March 23, 1999, all of which are incorporated herein

15 by reference.

(00035) Other embodiments include a method to enhance the expression of one or more cytokines or interleukins that facilitate Th1 immune responses in a subject or to reduce the expression of one or more cytokines or interleukins that

20 facilitate Th2 immune response in a subject comprising administering to the subject an effective amount of the composition of claim 32, whereby the subject's Th1 immune response is enhanced or the subject's undesired Th2 immune response is reduced ~~response is enhanced or the subject's undesired Th2 immune response is reduced~~.

25

(0002) This application is a divisional application under 37 C.F.R. 1.53(b) and claims priority from U.S. application Serial No. 09/535,675, filed March 23, 2000, now patent No. 6,667,299 B1, which claims priority from abandoned U.S.

provisional application Ser. No. 60/190,140, filed March 16, 2000, abandoned

5 U.S. provisional application Ser. No. 60/164,048, filed November 8, 1999, abandoned U.S. application Ser. No. 09/414,905, filed October 8, 1999, abandoned U.S. provisional application Ser. No. 60/140,028, filed June 16, 1999, and abandoned U.S. provisional application Ser. No. 60/126,056, filed March 23, 1999, all of which are incorporated herein by reference.

10

(00035) Other embodiments include a method to enhance the expression of one or more cytokines or interleukins that facilitate Th1 immune responses in a subject or to reduce the expression of one or more cytokines or interleukins that facilitate Th2 immune response in a subject comprising administering to the

15 subject an effective amount of the composition of claim 32, whereby the subject's Th1 immune response is enhanced or the subject's undesired Th2 immune response is reduced.